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Abstract 
 
Background  
BPS/IC is a chronic syndrome with bladder pain, divided into two main types: one with so called Hunner`s lesions (classic type) 
and one without (nonulcer type). In the recently presented ESSIC classification system the classic type, in focus of the present 
work, has the designation Type 3C BPS/IC. Symptoms are characterized by bladder pain, urgency, frequency and nocturia. The 
aetiology and pathophysiology of BPS/IC remain obscure and treatment is directed towards symptom relief. Intravesical 
instillation of dimethyl sulfoxide, DMSO, is an established treatment for BPS/IC and can be proposed as first-line treatment for 
patients with nonulcer BPS/IC. For patients with Type 3C, transurethral resection of lesions in the bladder, TURB, may render 
satisfactory symptomatic effect. Myofibroblasts might have a role in the evolution towards bladder contracture in patients with 
Type 3C BPS/IC and high levels of cytoplasmatic α-smooth muscle actin, α-SMA, are consistent with a typical myofibroblast 
phenotype. In patients with Type 3C, fibrosis of the bladder may represent end-stage disease. At this stage conservative treatment 
is often no longer effective and reconstructive surgery may be necessary. 
 
Aim and methods  
The aims of this thesis were to investigate side-effects and outcome with first-line treatments for BPS/IC, especially 
in Type 3C BPS/IC. Data on patients were obtained from medical records and by telephone interviews. 
Immunohistochemical techniques were employed to visualize mast cells and possible myofibroblasts. 
 
Results 
I. Side-effects after instillations of DMSO were common but transitory. Maintenance treatment with DMSO may 
offer long-term symptom improvement. 
 
II. For patients with end-stage Type 3C BPS/IC, the initial major surgical procedure resulted in complete symptom 
resolution in 82 per cent, in contrast to only 23 per cent of the patients with nonulcer BPS/IC.  
 
III. No statistically significant correlation between mast cell density in the lamina propria, urothelium or the detrusor 
and duration of symptom amelioration could be seen after the first, second or third TURB. There was a positive 
correlation between a high mast cell number in the urothelium at the third TURB and the risk of developing end-
stage disease. 
 
IV. No statistically significant increase or decrease in α-SMA positive or α-SMA negative fibroblast-like cells could 
be seen with increased number of TURB. An overweight of α-SMA positive fibroblast-like cells compared to α-
SMA negative fibroblast-like cells was identified at the third TURB, but only reaching a statistical significance in 
the group with patients who had not yet reached end-stage.   
 
Conclusions  
Intravesical instillation with DMSO appears to be associated with a reasonable degree of discomfort, when 
considering the potential benefit of the treatment in both subtypes of BPS/IC.  
For patients with Type 3C BPS/IC, TURB is potentially quite an effective treatment option. However, mast cell 
density does not appear to predict the duration of symptom amelioration after complete transurethral resection of 
Hunner`s lesions, neither in the lamina propria nor in the urothelium or the detrusor.  
The findings of an overweight of α-SMA positive fibroblast-like cells in patients with signs of active disease, 
expressed by repeated TURB`s, might represent a time dependent factor of myofibroblast activation eventually 
resulting in a contracted bladder.  
When conventional therapies no longer offer any symptom amelioration, in the patient with bladder contracture 
and/or intolerable symptoms, reconstructive surgery can be an appropriate last resort, however only in patients with 
Type 3C BPS/IC. The most important determinant in the decision to embark upon major reconstructive surgery is 
the assessment of subtype and stage of the disease. 
 
Keywords: interstitial cystitis, bladder pain syndrome, dimethyl sulphoxide, mast cells, myofibroblasts, transurethral 
resection, bladder substitution 
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 ABBREVIATIONS 
APF   anti-proliferative factor 
α-SMA   alfa-smooth muscle actin 
BCG   bacillus calmette-guerin 
BPS   bladder pain syndrome 
CP    chronic prostatitis 
CPP    chronic pelvic pain 
CPPS    chronic pelvic pain syndrome 
DNA    deoxyribonucleic acid  
EGF   epidermal growth factor  
ELISA   enzyme-linked immunosorbent assay  
ESSIC  Former European Society for the Study of Interstitial 
Cystitis, now International Society for the Study of 
Bladder Pain Syndrome 
FDA   food and drug administration  
GAG    glycosaminoglycans  
GP-51    glycoprotein 51 (molecular weight 51 kD) 
GRA   global response assessment 
H1R    histamine receptors 1 
H2R    histamine receptor 2 
HB-EGF   heparin-binding epidermal-like growth factor 
HC gp-39   human cartilage glycoprotein-39  
Htx-Eo    hematoxylin-eosin   
IBS   irritable bowel syndrome 
IC   interstitial cystitis 
ICPI   interstitial cystitis problem index 
ICSI   interstitial cystitis symptom index 
IGFBP3   insulin-like growth factor binding protein 3  
IGF-1   insulin-like growth factor 1  
IPG   implanted pulse generator 
MAP kinase   mitogen-activated protein kinases
MC TC   mast cell tryptase-positive, chymase-positive 
MCT   mast cell tryptase-positive, chymase-negative 
Nd:YAG   neodymium-doped yttrium aluminium garnet 
NIDDK  national institute of diabetes and digestive and kidney 
diseases 
NIH   national institute of health 
NO   nitric oxide 
OAB    overactive bladder syndrome  
PCR   polymerase chain reaction
PI3K   phosphatidylinositol 3-kinase 
PRV   pseudo rabies virus 
PUF   pelvic pain and urgency/frequency questionnaire  
SNS   sacral nerve electrical stimulation 
TENS   transcutaneous electrical nerve stimulation 
TNF   tumour necrosis factor 
TUR   transurethral resection 
VEGF   vascular endothelial growth factor 
WICI   wisconsin interstitial cystitis inventory  
YKL-40   Y (tyrosine)K (lysine) L(leucine) 40 kD 
ZO-1    tight junction protein 1 (zona occludens 1) 
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INTRODUCTION 
 
HISTORY 
The name interstitial cystitis (IC) was given to the disease by A.J.C. Skene, who described a 
condition characterized by “inflammation that destroyed the urinary bladder mucous membrane 
partly or wholly and extended to the muscular parity ", in his book on Diseases of Bladder and 
Urethra in Women published in 18871. 
Some time earlier in 1808, Philip Syng Physick had described an inflammatory condition of the 
bladder, and in 1836 the Philadelphian surgeon Joseph Parrish used the description "tic 
douloureux" of the bladder, a term used for painful neurological conditions such as trigeminal 
neuralgia. However, the person whose name has been most commonly linked with this syndrome 
is Guy Hunner, a Boston surgeon who described this inflammatory bladder disorder in a number 
of patients in 19152. He popularized the disease with the description of characteristic bladder wall 
ulcers and these lesions became to be known as Hunner's ulcers although the term “ulcer” is now 
considered to be a misnomer since in fact it is not a true ulcer. The first widespread 
epidemiological description of IC was done by Hand in 19493, who published an article on 
interstitial cystitis with a report on 223 cases, describing the widespread, small, submucosal 
bladder haemorrhages and the significant variation in bladder capacity. 
 
DEMOGRAPHICS AND CLINICAL PRESENTATION 
BPS/IC is a chronic disease affecting the function of the bladder. It predominantly affects 
middle-aged women but occurs in all age groups. It is rare in men4 but from the Mayo clinic a 
series of 123 cases in men over a 15 year period has been reported5. The disease may also be 
diagnosed in children6. Most studies also report the disease to be rare in black people7, 8. Familial 
occurrence of BPS/IC has been reported9. A hereditary aspect to incidence has been suggested 
by Warren et al10 in a pioneering study. He found that adult female first-degree relatives of 
patients with BPS/IC may have a prevalence of the syndrome 17 times that found in the general 
population. This together with previous reported evidence showing a greater concordance of 
BPS/IC among monozygotic than dizygotic twins suggests, but does not prove, a genetic 
susceptibility that could partially explain the discord in prevalence rates in different populations10, 
11. There is a delay between the onset of urinary symptoms and the diagnosis typically being about 
5 years4, 12, 13. The most obvious signs of BPS/IC are pain, urgency and urinary frequency (day and 
night). The pain is usually located supra- or retropubically. Occasionally the pain can be described 
to radiate into the loins or into the urethra or the vagina. In many cases voiding relieves the pain. 
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The urgency is sensory and often, but not always, due to the pain. Variability of urinary 
symptoms is common; with symptoms worsen periodically in 40–50 per cent of premenopausal 
women. Common triggers include psychological or physical stress14. Incontinence is rare and 
motor urge incontinence nearly excludes the disease. However, considerable amount of clinical 
characteristics are shared between BPS/IC and several other disease states, including; overactive 
bladder syndrome (OAB) (especially “OAB-dry”), chronic cystitis/urethral syndrome, chronic 
pelvic pain syndrome (CPPS) in women and CPP syndrome (CPPS)/chronic prostatitis (CP) in 
men15-17.  
There is increasing evidence that BPS/IC is a heterogeneous syndrome and owing to a new 
classification described later, patients with Hunner’s lesion on cystoscopy are referred to Type 3C 
BPS/IC. In this group of patients some develop contracted bladder. There is little known and 
described about this in the literature, although well known for decades. Some patients develop 
end-stage disease rapidly, characterized by fibrosis and fat involution on histopathological 
examination, but more commonly this result of the disease evolves over several years18. 
 
PREVALENCE 
Prevalence estimates for BPS/IC vary significantly due to how the studies are made; based on 
hospital record review, based on a mailed survey of board certified urologists or based on 
participant self-report. Estimates have ranged from 18.6/100,000 women older than 20 years in 
Finland 4 to approximately twice that in the United States19. In studies, with reported prevalence 
rates as high as 25 per cent 16, 20, investigators have moved toward prediction of BPS/IC 
prevalence based on symptoms consistent with the disease, rather than positive cystoscopic 
findings. Some argue that traditional epidemiologic studies have significantly underestimated 
BPS/IC prevalence, because they surveyed populations for diagnosed cases rather than screening 
for BPS/IC symptoms and evaluating suspected cases. The percentage of Type 3C BPS/IC of 
the total number of patients with BPS is not uniformly reported. Messing and Stamey reported 
Type 3C BPS/IC to account for about half of all cases12. Later, Type 3C BPS has been 
considered a rare finding, accounting for only 5-10 per cent of diagnosed cases21, whereas in our 
centre 50 per cent, a figure stable over years 86. Later in a very large US series, Type 3C BPS/IC 
comprised approximately 20 per cent22. 
 
COMORBIDITY AND NONBLADDER RELATED SYMPTOMS 
High risks of impairment of quality of life are reported, commonly affecting sexual life. Also, 
bowel disorders and psychological stress are correlated to the probability of BPS/IC23.  
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In several epidemiological studies an increase of other conditions, including the irritable bowel 
syndrome, anxiety disorders, allergies, fibromyalgia and rheumatological disorders, has been 
shown in patients with BPS/IC24-28. In a case-control study Erickson found that patients with 
BPS/IC had higher scores than controls for pelvic discomfort, backache, dizziness, chest pain, 
aches in joints, abdominal cramps, nausea, palpitations and headache29. Buffington theorizes that 
a common stress response pattern of increased sympathetic nervous system function in the 
absence of comparable activation of the hypothalamic-pituitary-adrenal axis may account for 
some of these related symptoms30. Common factors associated with BPS/IC, such as sleep 
deprivation and chronic pain, can possibly lead to some of the nonbladder related symptoms. It is 
unknown whether these symptoms share a common pathophysiology or whether they are results 
of having BPS/IC. However, several studies have concluded that patients with BPS/IC do not 
indiscriminately report high scores for multiple somatic complaints29, 31, 32. 
No reports have ever documented a relationship to suggest that BPS/IC is a premalignant 
disorder. 
 
PATHOLOGY/AETIOLOGY AND HYPOTHESIS 
The underlying pathophysiology of BPS/ IC is still incompletely understood. A number of 
theories of its pathogenesis have been suggested, but none entirely explain manifestations of the 
syndrome, and its exact aetiology is still unknown. It seems as if BPS/IC may have pluricausal 
aetiology and multifactorial pathogenesis. The previously explored aetiologies of IC include 
increased bladder epithelial permeability, mast cell activation, release of inflammatory mediators, 
subclinical infection, neuropathic changes, toxic compounds in the urine, impaired bladder 
vascular supply and autoimmunity.  Pathophysiologic concepts focus on increased permeability 
of the urothelium, neurotransmitter/neuropeptide release by the urothelial cells, bladder sensory 
nerve upregulation secondary to nerve inflammation and neuroimmunoendocrine inflammation 
with mast cell involvement. A possible starting event are thought to be an infective or other 
inflammatory insult that lead to loss of integrity at the epithelial surface of the bladder. Secondary 
to this, sensory nerve up-regulation and enhanced mast cell activation may occur. The closing 
stages of this process would be a form of regional neuropathy that can result in pain and voiding 
symptoms, as well as other manifestations, e.g. gynaecological and gastrointestinal.  
As indicated above, the aetiology of interstitial cystitis is unknown, but there are many theories 
concerning its aetiology and pathogenesis, some of which are discussed briefly below. 
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Fig 1 Hypothesis of possible pathophysiological events in BPS/IC. 
 
Leaky epithelium 
The urothelium has a number of levels of defences against low and high molecular weight 
solutes, including the dense layer of glycosaminoglycans and glycoproteins on the luminal layer, 
tight junctions, hydrophobic uroplakin plaques and active ion pumps. Mucus provides the 
immediate interface between urine and bladder wall and represents the primary barrier in the 
bladder for controlling interactions with urine. Bladder surface mucus is composed of 
glycosaminoglycans (GAGs) and proteoglycans on the outer surface of the transitional cell apical 
membrane, with about 80 to 90 per cent of the total surface glycosaminoglycan bound as integral 
membrane proteins33, 34.  
The role of mucus was first investigated in studies on the antibacterial defence mechanism of the 
bladder. With the use of acid or detergents containing solutions, mucus was removed and a 
marked rise in bacterial adherence and a resultant increase in bacterial infection could be seen35. 
Further studies showed that an anti adherence effect could be regenerated by exogenous 
substances after mucus removal36, 37. In a study by Parsons et al this hypothesis was confirmed by 
showing more than 22 per cent increased urea movement in patients with BPS/IC compared 
with normal individuals38. In patients with Type 3C BPS/IC it was even more increased. This was 
taken as strong evidence for an existing abnormal regulation of mucosal permeability in BPS/IC 
patients and that mucus is an important regulator of permeability to urinary cat ions and is 
dysfunctional in most patients with BPS/IC. 
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Urine potassium is by some considered to play a pivotal role in BPS/IC pathogenesis, being a 
potentially toxic component to the bladder muscles and nerves. The urine levels are quite high, 
ranging from 24 to 133 mEq/L, compared to normally only 4 mEq/L inside the bladder wall. 
When intravesical potassium was compared to sodium in a blinded fashion, normal subjects had 
no reaction to sodium or potassium before injury of the mucus with protamine. After protamine 
treatment 90 per cent of normal subjects reported urgency, compared to only 10 per cent of 
normal subjects who had any reaction to sodium39. These data was considered as evidently 
supporting the theory that potassium is the primary toxin accountable for causing the symptoms 
of BPS/IC.  
An excess of potassium ions in the suburothelial space is then accountable for the strong urge 
sensation in BPS/IC, originating from the chemosensitive C fibers. Typically, anticholinergics are 
ineffective in the treatment of these urge sensations since C fibers are not governed by the 
cholinergic system. Further verification for the potassium hypothesis is that evaluated levels of 
urinary potassium in normal patients versus those in newly diagnosed untreated patients with 
BPS/IC, show significantly lower levels of potassium in patients with BPS/IC. Urine potassium 
levels in patients with BPS/IC who were successfully treated were significantly higher than in 
newly diagnosed untreated patients with BPS/IC40. 
 
-Defect differentiation 
The apical layer of cells, the so-called umbrella cell layer, is known to be impermeable, but the 
molecular mechanisms that constitute this impermeability are far from completely identified. 
E-cadherin, which has a crucial role in urothelial differentiation41, ZO-1, which contributes to the 
impermeability of the bladder urothelium by forming tight junctions 42, 43, as well as uroplakin, the 
major hydrophobic urothelial protein found on the surface of umbrella cells and also contributes 
to bladder impermeability, 42, 44 has been studied. In the same study45  chondroitin sulphate, a 
component of the so-called glycosaminoglycan GAG layer that has been implicated to have a role 
in maintaining bladder impermeability and previously shown to be decreased in IC46 was also 
examined. Immunohistochemical labelling for ZO-1 tight junction protein, uroplakin, 
chondroitin sulphate and E-cadherin was performed and evidence was found for widespread 
abnormalities in the expression of proteins associated with urothelial defences and differentiation 
in 24 of 27 biopsy specimens. There is further evidence of the failure of the urothelium to 
generate the entire set of defence molecules normally produced by a mature urothelium; the 
GP51 glycoprotein (molecular weight, 51 kDa) is a major component of the bladder mucous 
layer that is produced mainly by bladder uroepithelial cells47, with 97 per cent of all GP51 
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produced within the bladder48. GP51 covers the epithelium and is secreted into the urine, as 
detected by immunohistochemistry and enzyme-linked absorbent assay (ELISA), respectively48, 49. 
GP51 also binds to gram-positive and gram-negative uropathogens and encapsulates or 
aggregates them50.  Immunohistochemical studies of bladder biopsy specimens comparing 
patients with BPS/IC versus normal controls reveal absent or decreased levels of GP51 in 
patients with BPS/IC versus a normal quantity of GP51 in the controls51. Interestingly, urine 
levels of GP51 are also noticeably decreased in patients with BPS/IC, with values similar to those 
in patients who undergo cystectomy48.  
Other evidence for abnormal epithelial cell growth factor levels in BPS/IC exists. Keay et al52, 53 
have demonstrated that BPS/IC patient urine specimens have significantly abnormal levels of 
some epithelial cell growth factors, including decreased levels of heparin-binding epidermal-like 
growth factor (HB-EGF), increased levels of epidermal growth factor (EGF), insulin-like growth 
factor 1 (IGF1) and insulin-like growth factor binding protein 3 (IGFBP3), compared with 
asymptomatic controls or patients with other urogenital disorders. These findings could explain 
the histological changes, with e.g. bladder epithelial thinning, seen on biopsy. In the same studies 
an inhibition of 3H-thymidine incorporation by normal human bladder epithelial cells, in 
response to urine from BPS/IC patients, was seen in 94 per cent compared with 9 per cent of 
urine from asymptomatic controls and 9 per cent of patients with other urogenital disorders. This 
then giving rise to evidence for a urinary toxin in BPS/IC that inhibits the proliferation of normal 
bladder epithelial cells in vitro significantly more often than specimens from controls53. 
When bladder epithelial cells from BPS/IC patients are grown in vitro, the same abnormal 
production in growth factors are seen, indicating that these changes are not a result from an 
extrinsic stimulus54. 
 
-Autoimmunity 
With BPS/IC being a non-infectious inflammatory disorder, coexisting with allergic disorders 
and affecting predominantly women, theories of an immunologic aetiology on autoimmune basis 
seem logical. IgM antibodies and complement have been identified in areas of endothelial cell 
damage55-57as well as IgA antibodies on the surface of bladder epithelium in BPS/IC patients, but 
the antigenic specificity of these antibodies is unknown. BPS/IC patients also do display, to a 
greater extent than in control, auto-antibodies in the sera but the specificity of these auto-
antibodies has differed between reports58, 59. Harrington et al60 examined local and peripheral 
immune response in bladder biopsies and peripheral blood, using a panel of monoclonal 
antibodies. Type 3C BPS/IC patients had ulcers, intense inflammation with focal sheets of 
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plasma cells, aggregates of T cells, B cell nodules including germinal centers, a decreased or 
normal helper-to-suppressor cell ratio and suppressor cytotoxic cells in germinal centers. 
However, no statistically significant difference between control and nonulcer group was 
identified. Flow cytometry analysis of peripheral blood lymphocyte subsets showed normal 
patterns in controls, but increased numbers of secretory Ig positive B cells and activated 
lymphocytes in both the Type 3C BPS/IC and nonulcer group. 
Studies, showing a common autoantigen in serum from patients with BPS/IC and those with 
atopic dermatitis (a Th-2-mediated skin disease) 61 or an increase in interleukin(IL)-6 in urine of 
patients with BPS/IC (a known stimulus of the Th-2 response)62, are by some thought to suggest 
that BPS/IC may be driven by a group of Th-2 cytokines leading to an immunopathologic 
response. In general, a Th-2 response is thought to be associated with disease states, supporting 
antibody development and tissue necrosis. In summary, data show that anti-epithelial cell auto-
antibodies are present in the urine of BPS/IC patients, but suggest that these antibodies may 
simply be the manifestation of non-specific antigenic products of cellular/tissue damage and 
probably not the primary cause of the disease. 
 
-Infection 
Urinary tract infection and BPS/IC share some features, such as predominance in women, 
irritative bladder symptoms, rapid onset and episodic course and nonspecific inflammatory 
histopathologic characteristics. A prospective, controlled study by Keay et al63 did not reveal the 
presence of a uniform bacterial species or of any Mycoplasma, Ureaplasma, Chlamydia, 
mycobacteria, anaerobic bacteria, or fastidious bacteria (including Gardnerella sp, Helicobacter 
sp, Campylobacter sp, Haemophilus sp, or Neisseria sp). Nor did any patient have evidence of 
active infection with herpes viruses (herpes simplex, cytomegalovirus, and varicella zoster), 
enteroviruses (poliovirus, coxsackie virus groups A and B, echovirus, and others), measles, 
mumps, rubella, or respiratory viruses (adenovirus, influenza A and B, respiratory syncytial, 
parainfluenza, and rhinovirus). These results concur with those of others64-66. 
Keay et al63 did find proof for the hypothesis that BPS/IC patients have a higher prevalence than 
controls of various microorganisms in their urine. However, that BPS/IC would be a result of 
the direct effect of virulence factor or factors of these organisms is somewhat questionable due 
to the fact that several different species of microorganisms were isolated, showing that no 
common factor or cluster of factors characterizes BPS/IC-associated organisms. Also, the 
organisms are non-pathogenic in normal hosts because of deficiency in known virulence factors. 
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Therefore, it seems more likely that these organisms may be pathogenic owing to an abnormal 
host response, either epithelial, inflammatory, or immune response.  
In a large study patients with BPS/IC/CPPS were screened for bacterial DNA and viral DNA 
sequences using PCR. Common urogenital pathogens such as eubacteria, cytomegalovirus, herpes 
simplex I, herpes simplex II, adenovirus, human papilloma virus (HPV) and Chlamydia trachomatis, 
which could be implicated in the aetiology of BPS/IC/CPPS, were selected. However, PCR were 
negative in all samples and the authors draw the conclusions that BPS/IC/CPPS is not associated 
with persistence of viral and bacterial DNA in the bladder and that a chronic infective aetiology 
for the condition is excluded67. 
 
-Nerve inflammation and mast cells 
Most studies in humans have shown an increase in mast cell numbers and activation in bladder 
biopsies from patients with BPS/IC 55, 68-71and the partial efficacy of neuromodulatory therapies 
suggests that neural-immune interactions are engaged in BPS/IC associated pelvic pain72, 73.  
Based on the presence or absence of tryptase and chymase in their granules, mast cells are 
classified as MCT ( tryptase-positive, chymase negative mast cell) and MCTC (tryptase-positive, 
chymase-positive mast cell)74. The MCT is mainly observed in the bronchial and nasal mucosa and 
MCTC in the skin. The type of mast cell dominantly present in the bladder of BPS/IC patients 
may be MCTC. In nonulcer BPS/IC, reports on bladder mast cells show large standard deviations 
while mast cells are more consistently increased in Type 3C BPS/IC75. The hypothesis is that 
activated mast cells are multifunctional cells competent of secreting a wide variety of preformed 
stores of immune mediators, such as vasoactive, nociceptive and proinflammatory mediators. 
Vasoactive and inflammatory mediators secreted by mast cells may explain many BPS/IC 
symptoms and produce neuronal sensitization and secretion of neurotransmitters that further 
stimulates mast cells. Mast cells and histamine receptors 1, H1R, and 2, H2R, have been 
demonstrated in a murine interstitial cystitis model, to cause pelvic pain originating from the 
bladder76, 77. In a limited trial of BPS patients, the H2R antagonist cimetidine produced significant 
improvement in pain and nocturia78 but in contrast to this clinical trials present with varying 
results, on patients receiving the old-line H1R antagonist hydroxyzine 79. 
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DIAGNOSING 
Diagnostic criteria have varied widely in the past. Historically, the strictest diagnostic criteria are 
those developed in 1987 and 1988 by the National Institute of Health (NIH), the so called 
NIDDK (National Institute of Diabetes, Digestive and Kidney Diseases) criteria, used in 
research definition of interstitial cystitis. To meet these criteria, both cystoscopy and cystometry 
are needed to exclude other possible causes for patient symptoms.  
 
Automatic inclusions  
Hunner's ulcer 
 
Positive factors
Pain on bladder filling relieved by emptying 
Pain (suprapubic, pelvic, urethral, vaginal, or perineal) 
Glomerulations on endoscopy 
Decreased compliance on cystometrogram 
 
Automatic exclusions
Bladder capacity > 350 mL on awake cystometry using either gas 
or liquid as filling medium. 
Absence of intense urge to void with bladder filled to 100 mL of gas 
or 150 mL of water during cystometry, using a fill rate of 3-100 mL/mm 
Demonstration of phasic involuntary bladder contractions 
during cystometry using fill rate described above 
Duration of symptoms less than 9 months 
Absence of nocturia 
Symptoms relieved by antimicrobials, urinary antiseptics, 
anticholinergics, or antispasmodics (muscle relaxants) 
Frequency of urination while awake < 8 times per day 
Diagnosis of bacterial cystitis or prostatitis within 3 month period 
Bladder or lower ureteral calculi 
Active genital herpes 
Uterine, cervical, vaginal, or urethral cancer 
Urethral diverticulum 
Cyclophosphamide or any type of chemical cystitis 
Tuberculous cystitis 
Radiation cystitis 
Benign or malignant bladder tumors 
Vaginitis 
Age < 18 years 
 
Table 1 NIDDK criteria 
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These criteria have allowed a reasonably homogeneous group of patients to be identified for 
research purposes but they have not been generally accepted as standard criteria and, as a 
consequence, prevalence estimates for BPS/IC vary significantly.  The NIDDK criteria have also 
generally been considered too strict to be used in clinical settings80. In fact, the diagnosis has been 
based on quite varying expert opinions. Therefore, ESSIC (International Society for the study of 
Bladder Pain Syndrome) have recently decided upon a new nomenclature, new diagnostic criteria 
and a new classification for the syndrome formerly called interstitial cystitis (IC). The new 
nomenclature for the disease is bladder pain syndrome, with the advantage of not having a name 
of the disease implying inflammation. However, a patient with the Hunner type of disease 
actually fulfils the requirements of the original term of IC, displaying lesions and bladder 
interstitial inflammation of the bladder. With the new ESSIC nomenclature patients who displays 
Hunner`s lesions on cystoscopy are referred to as Type 3C BPS/IC. 
 
Patient selection      
Patients with pelvic pain, pressure or dicomfort  
perceived to be to related to the urinary bladder  
accompanied by at least one other urinary symptom  
such as persistent urge to void or frequency 
  
? 
  
Exclusion of confusable diseases      
Medical history, physical examination, urinanalysis,  
urine cultures, PSA in males over 40 yrs, uroflowmetry,  
post-void residual urine volume by ultrasound scanning,  
cystoscopy and biopsy  
 
? 
  
Classification of BPS  
cystoscopy with hydrodistension and biopsy if indicated  
Cystoscopy findings Biopsy findings
x: not done x: not done 
1: normal A: normal 
2: glomerulations grade II or III B: inconclusive 
3: Hunner`s lesion (with or without glomerulations) C: inflammatory infiltrates, granulation tissue,  
 detrusor mastocytosis or intrafascicular fibrosis 
 
Table 2 ESSIC nomenclature, diagnostic criteria and classification 
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Symptoms 
Earlier distinction was made between two subtypes: ulcerative (classic, Type 3C BPS/IC) and 
non-ulcerative variants81, 82. Type 3C BPS/IC is generally being reported as being more 
uncommon, with prevalence ranges from 3,5 to 56 per cent in different studies3, 12, 82-85. Patients 
with nonulcer subtype are younger at diagnosis and symptom onset. Both average functional 
bladder capacity and average bladder capacity under general anaesthesia are significantly larger for 
patients with nonulcer disease. Nonulcer disease does not progress into Type 3C BPS/IC82.  The 
two entities usually do not differ in symptom pattern, but e.g. sharp pain, pain relieved by 
urinating and hematuria, are all symptoms being more common in Type 3C BPS/IC. Pain 
relieved by standing, IBS, dull aching pain and dyspareunia are all symptoms being more 
common in nonulcer IC. However, no variable alone can discriminate between the two subtypes 
with high sensitivity and specificity and are therefore just epidemiological data that can support 
cystoscopic findings22. Logadottir et al has demonstrated that a subclassification between classic 
and non-ulcer disease, without cystoscopy, can be made by measuring a difference in intraluminal 
nitric oxide (NO) evaporation in patients meeting the NIDDK criteria86. Hosseini et al87 showed 
a statistically significant correlation between changes in symptom/problem IC index score and 
changes in luminal bladder NO in each patient after treatment with oral prednisolone for 8 
weeks, suggesting that NO also can be used to evaluate treatment responses in individual patients 
with Type 3C BPS/IC objectively.  
 
Cystoscopy and biopsy 
In Type 3C BPS/IC single or multiple reddened mucosal areas are seen with small vessels 
radiating towards a central scar, fibrin deposit or coagulum. With increasing bladder distension 
this site ruptures, resulting in petechial oozing of blood from the ulcer and the mucosal margins. 
Post distension a rather typical, bullous oedema develops. Histological specimens obtained from 
such lesions display urothelial spongiosis and detachment, subepithelial, perineural and 
perivascular deposits of mononuclear cells and a characteristic mast cell response with increase of 
such cells in the detrusor muscle and in the lamina propria55, 88. 
 
20 
  
Fig 2 Distinct mastocytosis of lamina propria on tryptase stain (A), complete denudation of urothelium (B), 
granulation tissue in lamina propria (C), edema in lamina propria (D), dense lymphocytosis of lamina propria on 
leukocyte common antigen stain (E) and small nerve proliferation in lamina propria on S100 stain (F). 
 
In contrast, in patients with nonulcer BPS/IC a normal bladder mucosa is seen at initial 
cystoscopy. During or after hydrodistension small, multiple glomerulations and multiple 
superficial petechial bleedings occur. However, glomerulations have been reported to be present 
in healthy women after bladder distension89. In some patients, confluent, superficial mucosal 
cracks develop during distension. Histopathological changes like those found in Type 3C BPS/IC 
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are absent. Mainly, there is slight or no mast cell involvement. Small suburothelial bleedings and 
tiny cracks in the mucosa may be seen in accordance with the cystoscopic findings55, 88. 
 
Urine markers 
The finding that cells from the bladder lining of normal controls grow significantly more rapidly 
in culture than cells from BPS/IC patients led Keay et al90 to the discovery of an anti-proliferative 
factor, APF, produced by the urothelium of BPS/IC patients. Normal bladder cells were cultured 
in the presence of urine from patients with BPS/IC, asymptomatic controls, bacterial cystitis and 
vulvo-vaginitis. Only urine from BPS/IC patients inhibited bladder cell proliferation. The 
presence of APF was found to be a sensitive and specific biomarker for BPS/IC53. APF activity 
dropped significantly in BPS/IC patients within two hours after hydrodistension91 and after five 
days of sacral neuromodulation92. APF has been purified and proved to be a frizzled 8 protein 
that belongs to a newly discovered family of proteins which seem to be important in the 
development of nerve tissues, skin, and the linings of organs93. 
 
Questionnaires 
The O’Leary-Sant IC Symptom (ICSI) and O’Leary-Sant IC Problem Indexes (ICPI) and the 
Wisconsin IC Inventory (WICI)31, 94 are the most commonly used instruments to assess overall 
symptoms in BPS/IC. The two O’Leary-Sant indexes are intended to assess symptoms and their 
impact on patients’ quality of life, respectively. The WICI is implanted in a longer questionnaire, 
including other body systems, and is based on seven questions associated to urinary symptoms. 
Measures of pain, urgency and frequency are also used as outcomes in BPS/IC research. The 
three scales have been validated.31, 94, 95 The ICSI, ICPI, and WICI have also been shown to be 
responsive to change over time as measured by global response assessment (GRA) in patients 
with BPS/IC and are therefore suggested as secondary endpoints for future clinical trials96. 
 
“Screening-tools” 
Two validated symptom-based tools can be used to screen the general patient population for 
BPS/IC; the Pelvic Pain and Urgency/Frequency (PUF) questionnaire and O'Leary-Sant (OLS) 
IC symptom and problem index. The PUF questionnaire consists of a symptom component and 
a problem component, which together yield a total score16, while the latter focuses on four 
symptoms, namely, urgency, frequency, nocturia, and pain. The problems arising from each of 
these four symptoms is scored and a total score is then calculated94. 
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TREATMENT 
Because of various theories of pathogenesis proposed for BPS/ IC, a large range of treatments 
have developed. These include oral medication, intravesical or bladder instillation therapy, dietary 
changes, lifestyle interventions, peripheral or transcutaneous nerve stimulation, hyperbaric 
oxygen therapy and surgical intervention. The guidelines for BPS/IC primarily recommend the 
use of medical therapies, including heparinoids, tricyclic antidepressants and antihistamines. 
These are often used in combination. Intravesical therapies and sacral neuromodulations are 
considered as adjuncts and surgery should be preceded by a methodical preoperative assessment, 
stressing evaluation of subtype. The benefits of combination therapy, with simultaneous 
addressing of a number of pathophysiological steps described in the disease, are recommended 
by some. Although lack of proof of knowledge in the literature, synergisms between medical 
therapies are theoretically probable, because many medications aim at treat different symptoms 
(e.g., pain, sleep difficulties, associated allergic phenomena).  
CLINICAL SUSPICION OF BPS/IC
  •Detailed history 
•Micturition chart 
•Cystometrography 
•Cystoscopy during anaesthesia + biopsies
Type 3C BPS/IC Nonulcer  
TURB  
Good 
Follow-up when 
demanded by the 
patient. 
Repeated TURB 
at recurrence. 
Repeated 
TURB. 
Additional 
treatment 
between TURB: 
•DMSO 
•Cystistat 
•Elmiron 
Inadequate responders due 
to bladder contracture 
Supratrigonal 
cystectomy and 
enterocystoplasty 
 Subsequent development 
of bladder contracture
TENS Responders 
Continuing intermittent TENS. 
Individual tayloring of treatment regimen 
Inadequate 
responders 
  •DMSO 
•Cystistat 
•Elmiron
Responders 
Follow-up when 
demanded by the 
patient 
Inadequate 
responders 
Urinary diversion and, if 
unrewarding, subsequent 
cystourethrectomy 
Type 3C  
Nonulcer 
Inadequate 
 
 
Fig 3 Treatment algorithm for BPS/IC 
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ORAL MEDICATIONS  
Sodium pentosanpolysulphate, PPS 
The mechanism of PPS is believed to substitute for a defect in the glycosaminoglycane (GAG) 
layer. Sodium pentosanpolysulphate (PPS) (Elmiron®) has been evaluated in double-blind, 
placebo-controlled studies and is the only oral medication approved by the US Food and Drug 
Administration (FDA) for use in the treatment of patients with BPS/IC. Subjective improvement 
of pain, urgency, frequency but not nocturia was reported in patients taking the drug as compared 
to placebo97, 98. However, conclusions from different studies on PPS are difficult due to 
differences among study designs, end points, missing data handling and furthermore, data are 
contradictory. In a later multicenter placebo controlled study, low global response rates for 
sodium PPS as well as for hydroxyzine suggest that neither provided benefit for the majority of 
the patients79. In this context it is also worth noting that, because of lack of rigorous inclusion 
criteria in various studies, severe obstacles remain when trying to extract valid conclusions.   
PPS is routinely administered at 300 mg/day in 2 or 3 separated doses and the response appears 
to be associated with the duration of therapy rather than the dosage99. 
 
Hydroxyzine 
The hypothesis behind treatment with hydroxyzine, a tricyclic, H1-receptor antagonist, is that the 
activation of mast cells seen with seasonal allergies may provoke symptom flares in individuals 
with BPS/IC and that antihistamine therefore could be an option in the treatment. The first 
report on treatment with hydroxyzine was in 1958100. Hydroxyzine is the only antihistamine that 
has the capacity to prevent mast cell activation and when used continuously, it suppresses mast 
cell degranulation101. The effect of hydroxyzine has not been evaluated in placebo-controlled 
studies except for the one previously mentioned, where no significant improvement was seen 
with treatment of hydroxyzine compared to placebo. This study was impaired by a probable type 
II error due to under-powering. However, because of lack of major side effects, wide availability 
and low cost it still has a role in the arsenal of BPS/IC treatments.  
The standard starting dose is 25 mg daily, taken in the evening to minimize the sedative effects.  
 
Cimetidine 
Cimetidine is a H2-blocker that has been evaluated clinically in a double-blind study with oral 
cimetidine versus placebo for three months. Those receiving cimetidine had a significant 
improvement in symptom scores, pain and nocturia. However, histologically the bladder mucosa 
showed no qualitative changes in either group78. 
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Amitriptyline 
Tricyclic antidepressant such as amitriptyline is thought to be effective in BPS/IC for 
mechanisms beyond its anxiolytic effect, such as blockade of acetylcholine receptors, inhibition 
of reuptake of released serotonin and norepinephrine and blockade of the histamine H1 receptor.  
The first report on amitriptyline in the treatment for BPS/IC was promising, showing a 
significant improvement in pain and daytime frequency but also resulting in virtually total 
remission of symptoms in 32 per cent of the patients (8/25), after being on the drug for 4 to 28 
months102. In a more recent prospective, randomized, placebo controlled, double-blind study by 
van Ophoven, a statistically significant change in the O'Leary-Sant IC symptom and problem 
index and statistically significant improvement of pain and urgency intensity compared with 
placebo could be seen103. In another study by the same researchers, considering patients reporting 
improvement in a global response assessment questionnaire as responders, the response rate was 
64 per cent (60 patients) with an overall mean dose of 55 mg. Likewise, the therapeutic response 
to amitriptyline was observed in patients fulfilling the NIDDK criteria as well as in those with a 
clinical diagnosis of BPS/IC104. 
Amitriptyline can be given at a starting dose of 10 to 25 mg daily in the evening. After several 
weeks, the dose can be titrated up in an attempt to maintain a balance of pain/irritative symptom 
reduction and adverse effects (i.e. fatigue, constipation, palpitations, weight gain, and urinary 
retention). Satisfactory results are usually achieved with doses in the range of 10 to 75 mg daily 
taken at night.  
 
INTRAVESICAL INSTILLATIONS 
Dimethyl sulphoxide, DMSO 
The chemical solvent DMSO is a lipid and water-soluble liquid that penetrates cell membranes. 
Its mode of action is not fully understood but has been suggested to be, except for purely 
analgesic, also anti-inflammatory, collagenolytic and muscle relaxantic. It is also a scavenger of 
the intracellular OH radical believed to be an important trigger of the inflammatory process.  
In a crossover trial105, patients were randomly allocated to instillations with 50 per cent DMSO 
solutions and placebo. Subjective improvement was noted in 53 per cent versus 18 per cent and 
objective improvement in 93 per cent versus 35 per cent, following DMSO and placebo 
treatment, respectively. DMSO is contraindicated during urinary tract infections or shortly after 
bladder biopsy and it temporarily causes a garlic-like odour. A case of pigmented eye lens 
deposits possibly caused by DMSO treatment has been reported106. 
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 DMSO is typically given at an initial dose of 50 mL weekly for 6 to 8 weeks, followed by a 
maintenance regimen of 50 mL every 2 weeks for 3 to 12 months. To potentially enhance the 
beneficial effects of the DMSO solution other compounds, such as methylprednisolone and 
heparin sulphate, can be added107.   
  
Bacillus Calmette-Guèrin 
BCG treatment involves marked elevation of IL-1, IL-2, interferon-gamma, and tumour necrosis 
factor, known stimulants of the Th-1 response108, 109. Thus, the efficacy of BCG in treating 
BPS/IC has speculatively been thought to be due to stimulation of Th-1 cytokines, allowing for 
correction of the underlying abnormal immunologic event, and promoting reparative conditions.  
In a study by Peters et al in 1997, BCG was shown to be safe and efficacious in the treatment of 
BPS/IC and therefore BCG was put forward as a potential promising treatment option for 
patients with IC110. In a follow-up study of the patients who responded favourably, 89 per cent 
(8/9) continued to have an excellent response with follow-up ranging from 24 to 33 months and 
BCG did not worsen symptoms in nonresponders111. However, in a later prospective, double-
blind crossover trial of BCG and DMSO, BCG treatment seemed not to be of any benefit of the 
patient112. These negative results were later corroborated in a large placebo study including 265 
subjects, showing that the treatment was tolerable but with quite low response rate113. 
 
Pentosanpolysulphate   
Pentosanpolysulphate (PPS) is a glycoprotein aimed at repairing the glucosaminoglycan (GAG) 
layer in BPS/IC bladders and is thereby thought to potentially diminish the effects that noxious 
agents in urine have on underlying sensory nerves of the bladder wall (C- and A-δ fibers). The 
bioavailability of PPS is poor after oral administration, hence the intravesical application. The 
efficacy of PPS has been studied in a double-blind placebo-controlled study including 20 patients. 
At three months, the only parameter showing a statistically significant increase in patients treated 
with PPS was the cystometric bladder capacity114. PPS was given as 300 mg in 50 mL OF 0, 9% 
saline, and twice a week for three months.  
 
Hyaluronic acid 
Treatment with hyaluronic acid, a natural proteoglycan, is aimed at repairing defects in the GAG 
layer. A wide range of epithelial-coating techniques including the use of heparin, sodium 
pentosan polysulfate, and hyaluronic acid have been used. Many reports suggested a long-lasting 
moderate efficacy with no significant toxicity115-121 However, available studies are limited in 
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number and quality and no randomized, placebo-controlled trials evaluating the use of 
intravesical hyaluronic acid exists. Patients usually receive four to six weekly intravesical 
installations of hyaluronic acid at a dose of 40 mg in a volume of 50 ml of phosphate-buffered 
saline. Responders then receive monthly doses. 
 
Chondroitin Sulphate 
Chondroitin sulphate, to substitute for the GAG layer defect, has been evaluated in two non-
randomized, uncontrolled pilot studies, both of them reporting improvements in patient-reported 
symptoms after the use of chondroitin sulphate. In one of the studies, a total of 6/13 (46.2 per 
cent) showed a good response, and 1/13(7.7 per cent) showed no response122. Sorensen et al123 
seemed to show more promising results, with average symptom improvement of 73.1 per cent 
(range 50 to 95 per cent) reported in 20 patients completing the trial, when using high dose (2.0 
per cent) chondroitin sulphate instillations in some patients instead of 0.2% solution. 
 
Vanilloids/ Resiniferatoxin (RTX) 
RTX is derived from a cactus named Euphorbia resinifera, and is an ultra potent analogue of the 
chili pepper extract capsaicin. RTX are vanilloid agonists that perform their action by activating 
the transient receptor potential vanilloid type 1 (TRPV1) receptor. They are meant to desensitize 
the TRPV1 receptor so pain transmission through C-fibers is prevented124. RTX is more potent 
than capsaicin in desensitizing C-fibers with less irritation. Clinical efficacy was demonstrated 
clearly in studies of small sample size125, 126. In a placebo-controlled trial on patients with pain and 
hypersensitive bladder disorder, RTX reduced symptoms such as nocturia, pain and frequency by 
approximately 50 per cent127. However, in a more recent study with the same design, RTX was 
not found to be effective in BPS/IC128. 
 
SURGICAL TREATMENT 
Bladder distension 
Hydrodistension of the bladder was first reported as an effective treatment of IC by Bumpus et al 
in 1930129, but the mode of action is still unknown. The initial intention with the procedure was 
to increase bladder capacity simply by stretching the detrusor and simultaneously inducing 
ischemic necrosis of sensory nerve fibers, accomplishing decreased bladder pain.  
Although many of the following series were small with dissimilarities in techniques, inclusion 
criteria and follow-up, the treatment regimen was accepted maybe mostly due to the fact that it 
represents a simple method with few complications. Complete absence of symptoms was claimed 
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to be achieved in 64 per cent (16/25) using the Helmstein method130, where an intravesical 
balloon is distended at the level of systolic blood pressure for three hours. However, bladder 
rupture occurred in two cases. This, together with the results of others, not using the Helmstein 
method, though, who failed to demonstrate any improvement later led to rejection of the 
treatment because of lack of efficacy and a high complication rate131, 132.  
 
Electrical stimulation 
The bladder wall contains visceral parasympathetic afferents in the form of lightly myelinated Aδ 
fibers and unmyelinated C fibers, possessing predominantly mechanosensitive (tension) and 
chemosensitive (nociception) properties, respectively133. Upon bladder filling, Aδ fibers respond 
to physiologic low-threshold intravesical pressure, whereas C fibers are typically silent. In animal 
models, unmyelinated bladder afferents exhibit impulse transmission following chemical 
irritation, and in the presence of significant epithelial inflammation may exhibit both spontaneous 
activity and novel mechanosensitivity134, 135. Such C fiber plasticity may play a role in the evolution 
of BPS/IC symptoms. Physiologic bladder filling in the presence of chronic inflammation could 
produce an afferent storm resulting in frequency, urgency and pain.  
Electrical stimulation is thought to function in part through the inhibition of C fiber impulse 
transmission to the central nervous system. Inhibition of C fiber transmission by sacral 
neuromodulation may occur as a result of primary somatic afferent activation, as typically 
employed SNS impulse parameters exhibit an affinity for somatic (versus visceral) and afferent 
(versus efferent) nerve fibers136, 137. Somatic afferent inhibition of C fiber transmission may be 
explained by the ‘gate theory’, introduced in 1965 by Melzak and Wall138. By stimulating more 
easily excitable afferents from the painful area, the artificial stimulus competes with and blocks 
the pain impulses. The stimulus may simultaneously elicit autonomic nerve effects like inhibition 
of detrusor activity139. Another possible mechanism is the release of opiates, especially 
endorphins. 
 
Transcutaneous electrical nerve stimulation, TENS, is administered with high frequency 
stimulation (50-100 Hz) by electrodes above the pubic bone, and is applicable at the outpatient 
clinic. Patients with Type 3C BPS/IC have shown to respond more favourably than patients with 
nonulcer BPS/IC140, 141.  
Sacral nerve electrical stimulation, SNS, involves application of electrodes within the sacral 
foramina three or four, S3 or S4. As a first step an electrode is inserted into a relevant sacral 
foramen and stimulation is given by an external pulse generator. If good subjective effect is 
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achieved under a test period of some days or weeks, the sacral nerve electrode is connected to a 
subcutaneously implanted pulse generator, IPG, for long-term use. 
In a study including 78 patients with BPS/IC, with a median follow up was 61.5 months, a good 
long-term success was seen in 72 per cent of the patients 142. The revision rate was 50 per cent 
and the explantation rate was 28 per cent, with the most common reason for explantation being 
poor outcome (54 per cent of the failed patients). Even better long-term results have been 
reported by others with similar follow up143. Also, both reduced symptoms and narcotic 
requirement in refractory BPS/IC patients have been achieved with long-term treatment144.  
 
Transurethral resection and coagulation 
Peeker et al18 retrospectively evaluated 103 patients with Type 3C BPS/IC and their response to 
complete transurethral resection of visible lesions in the bladder. In that series, a satisfactory 
symptomatic effect in 9 of 10 patients could be seen. This was in concordance with earlier fairly 
small studies on TURB and laser fulguration, that also resulted in favourable symptomatic 
outcome145-148. Interestingly, the included patients seemed to be suitable for division into four 
relatively distinct groups; long-term good responders (long-term remission for 3 years or more 
with a maximum of three resections), short-term good responders (need for repeated resections 
to stay symptomatically relieved and follow up less than 3 years), patients with bladder 
contracture (developed over more than 2 years) and end-stage disease (within 2 years after 
diagnosis). TURB has been suggested to result in symptom improvement by the removal of 
intramural nerve endings engaged by the inflammatory process. Surgical complications are rare, 
the most common being bladder perforation and prolonged postoperative hematuria. 
Neodymium (Nd):YAG laser has been used in urology since the 1960`s and Shanberg et al 
initially used it in 1985 for treatment of interstitial cystitis148. Laser ablation penetrates 
approximately 5 mm, heating tissue to 60-70C, thought leaving the underlying elastic fibers 
undamaged. Laser is among some considered advantageous over TURB since the operation is 
easier to perform with this technique and since it is debated which technique, if repeated, entails 
the greater risk of inducing bladder contracture. In the treatment of superficial bladder 
carcinoma, a cost analysis of Nd-YAG laser versus transurethral resection treatment showed that 
the main savings of laser versus TURB were a significantly shorter hospitalization and the 
elimination of the need for catheter drainage in almost all of the patients treated with laser 
therapy149. 
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Supratrigonal/subtrigonal cystectomy or urinary diversion 
In patients no longer responding to conservative treatment, reconstructive surgery has been 
reported to be successful in some cases. However, surgical therapy of BPS/IC should never be 
considered as a first-line therapy, and is only applicable in 2 to 10 per cent of patients with 
BPS/IC who fail to respond adequately to conservative management26, 150, 151. Initially, simple 
augmentation of the bladder with enterocystoplasty was carried out, similar to the “clam” 
enterocystoplasty used in the treatment of neurogenic and idiopathic detrusor overactivity. 
However, this procedure frequently failed, with recurrence of symptoms, and this led to the idea 
that the diseased bladder should be removed prior to augmentation of bowel.  Assessment of 
bladder capacity will provide a good indication as to the progression of inflammation-induced 
contraction of the bladder as a whole, as bladder capacity is the best prognostic indicator for 
major surgical intervention in BPS/IC. Performing reconstructive surgery in patients with large 
bladder capacity, a finding typical of nonulcer BPS/IC, has been questioned152. In a small study, 
Peeker et al153 showed that in patients with Type 3C BPS/IC, supratrigonal resection and 
subsequent augmentation is often successful, but typically patients with nonulcer BPS/IC have 
residual symptoms after this sort of procedure. 
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AIMS 
 
1. To describe the degree of discomfort with intravesical DMSO instillations and long-term 
efficacy results associated with the treatment  
(Paper I) 
 
 
2. To evaluate the outcome in patients, with long follow-up, after various types of 
reconstructive surgery in patients with Type 3C and nonulcer BPS/IC 
(Paper II)  
 
 
3. To assess mast cell density in lamina propria for correlation with duration of symptom 
amelioration after TURB in patients with Type 3C BPS/IC  
(Paper III) 
 
 
4. To describe prevalence and change in density of possible myofibroblasts in native 
resections and following repeated resections from patients with Type 3C BPS/IC  
(Paper IV) 
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PATIENTS 
 
Paper I: 
Twenty-eight patients, 13 (eleven women and two men, mean age at diagnosis 63, range 36 - 80 
years) with Type 3C BPS/IC and 15 (13 women, two men, mean age at diagnosis 45, range 24 – 
61 year) with nonulcer disease, who had received at least six instillations with DMSO were 
included. Bladder capacity at diagnosis under general anaesthesia was 568 ml and 863 ml for the 
two subtypes. Functional capacity at the beginning of treatment was 209 ml and 315 ml, 
respectively. The patients had been diagnosed according to the NIH-NIDDK criteria and were 
subdivided into the two different subtypes.  
 
Paper II: 
Thirty-four patients with Type 3C BPS/IC and 13 patients with nonulcer BPS/IC who had 
undergone reconstructive surgery during a 25 year period were included. Patients diagnosed 
before 1987 were included if found to conform to the NIDDK criteria. There was a typical 
female predominance. Patients with nonulcer disease were significantly younger than patients 
with Type 3C BPS/IC, both at symptom onset and at surgery. Preoperative functional capacities 
and bladder capacities under general anaesthesia were significantly larger in nonulcer patients 
compared to those with Type 3C BPS/IC. 
Patients were preoperatively assessed by interviews, visual analogue pain scales, 48h micturition 
diaries, urinalysis, intravenous urography, urethro-cystoscopy and bladder distension during 
anaesthesia including biopsies and in selected cases urodynamic evaluation.  
 
 Initial surgery Type 3C Nonulcer  
Supratrigonal cystectomy and ileocystoplasty 20 3 
Noncontinent uretero-entero-cutaneostomy 11 1 
Continent cutaneous stoma 1 9 
Caecocystoplasty  1 0 
Continent orthotopic diversion  1 0 
 
Table 3 Surgical methods 
 
Paper III/IV: 
The study included twelve patients, eight women and four men, diagnosed and treated between 
June 2003 and June 2009. All had undergone three consecutive complete transurethral resections, 
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the first one also being diagnostic. Bladder capacity at diagnosis under general anaesthesia was 
measured after distension to full capacity at 70 cm water. All patients fulfilled the NIH-NIDDK 
criteria 154 and the ESSIC BPS/IC Type 3C criteria; they had Hunner`s lesions and biopsy 
findings with inflammatory infiltrates, granulation tissue and detrusor mastocytosis. After the first 
TURB the patients were instructed to report symptom relapse. If so, they were scheduled for 
repeated TURB.  
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METHODOLOGICAL CONSIDERATIONS 
All patients were diagnosed according to the NIH-NIDDK criteria and subdivided into the two different subtypes 
on the basis of clinical, endoscopic and histopathological criteria (Paper I -IV).  
Paper I: 
In order to assess the most prevalent side effects of DMSO instillation treatment, a score system 
was adopted with one point given for every side effect (fever, hematuria, shivering, nausea and 
urethral irritation) reported and zero point if no side effect was experienced. Sensation of urethral 
burning/pain subsiding within 24 hours was also given one point, whereas if lasting more than 
one day, two points were given. Side effects were evaluated after each instillation; hence, maximal 
score after one instillation was 6 and minimal score 0. The scores after each instillation was added 
up resulting in a maximal total score of 36 during one series including six instillations.  From the 
total scores a median side effect score was calculated. Attention is to be drawn to the unfortunate 
fact that the sum resulting in the total score of 42, described in the published article, is wrong. 
 
Six weekly instillations of 50 ml DMSO-solution, 500 mg dimethyl-sulfoxide per ml, were 
administered. A Lofric Ch 8 catheter or a Conveen Easi Ch 10 catheter was used.  
Data were obtained by retrospectively surveying the clinical records. Evaluation included two 
micturition diaries, before as well as after the series, VAS of pain and registration of side effects 
after each instillation in every series. Three patients received only three instillations and one 
patient four instillations because of a marked aggravation of symptoms or failure to experience 
any symptom resolution. A follow-up telephone interview was conducted for patients who were 
successfully treated with DMSO and these patients were asked to fill in VAS and micturition 
diaries for two consecutive days. 
 
Paper II: 
Data were retrospectively obtained by surveying the clinical records. Various surgical procedures 
were made; noncontinent ureteroenterocutaneostomy, supratrigonal cystectomy and 
ileocystoplasty, continent urinary diversion (Kock pouch), continent orthotopic diversion and 
caecocystoplasty, depending on the patient’s age, health status, symptoms and to some extent 
also on when, during the 25 year period,  the procedure was performed. The type of surgical 
procedure was dictated primarily by subtype classification. For patients with BPS/IC and normal 
bladder capacity, supravesical diversion procedures were chosen and primarily patient’s age 
determined whether a continent or noncontinent type of diversion was to be performed. Five 
patients were excluded because they were lost from follow-up. 
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Reconstructive surgery- surgical techniques 
Supratrigonal cystectomy and ileocystoplasty/ Caecocystoplasty 
Via lower midline laparotomy incision the bladder is dissected free from peritoneum, while 
partially filled to facilitate the dissection. The bladder is incised and the ureteric orifices identified 
and catheterized for protection and for easier identification of the intramural portion of the 
urether. Subtotal resection of the bladder is then performed, leaving only the internal urethral 
meatus and both urethral orifices. A 40-cm segment of the ileum is isolated, approximately 30 to 
40 cm from the ileocaecal valve. Alternatively, an ileocolic segment cystoplasty can be fashioned. 
The isolated bowel, on its mesentery, is then detubularized along its antemesenteric border, 
sutured and double-folded to a spherical shape and anastomosed to the trigone remnant. 
 
Noncontinent uretero-entero-cutaneostomy 
A 15-25 cm length of ileum is chosen for a conduit, approximately 30 cm from the ileocecal 
valve, and removed from continuity with the bowel, maintaining the conduit’s vascular pedicle. 
The ureters are identified and cut. Both ureters are mobilized, and as the conduit is classically 
brought out on the right side of the abdominal wall, the left ureter is passed below the mesentery 
of the descending colon to the right side of the abdomen. Both ureters are then anastomosed to 
the afferent end of the conduit and its efferent end is brought through the abdominal wall to 
form a cutaneous stoma. 
 
Continent urinary diversion 
A 70 cm ileum segment is isolated approximately 50 cm proximal to the ileocecal valve. 
Approximately fifteen centimetres of the distal portion of the isolated loop are preserved for the 
outlet and continence nipple valve. The proximal fifteen centimetres of the segment are 
preserved for the construction of the afferent intestinal segment and the reflux nipple valve. The 
40 cm-long segment in-between is detubularized antimesenterically and used for the construction 
of the reservoir. 
 
Continent orthotopic diversion 
This technique is performed much like the one described above for continent urinary diversion, 
with the exception that the distal portion is anastomosed to the urethra.  
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Paper III/IV 
TURB 
Bladder capacity under general anaesthesia was measured after distension to full capacity at 70-80 
centimetres of water. An arbitrary value of 250 ml was set as the upper limit for bladder 
contracture (Paper IV). The median time of improvement in months after each 
TURB was measured and the entire group of patients was thereafter dichotomized based on the 
median value of symptom amelioration, referred to as fair responders or short-term responders 
(Paper III). Complete TURB of all lesions and the adjacent zone of oedema reaction were 
performed using a low-pressure continuous irrigating resectoscope. Complete resections, at as 
low current intensity as possible, were made with care taken to include adjacent zone of post-
distension oedema and obtain large strips to include half or more of the underlying detrusor 
muscle. In this way, prerequisites for obtaining sufficient material for histological examination 
were obtained.  
Histological examination and immunohistochemistry 
The histological examinations were made on series of 4 μm tissue sections and were cut from 
paraffin embedded bladder biopsies that were deparaffinised and stained with mouse monoclonal 
anti-human antibody against mast cell tryptase (Paper III) and smooth muscle cell actin (Paper 
IV). Counterstaining with Htx-Eo and Van Gieson was performed prior to dehydration and 
mounting with cover slips. The histologic specimens were examined and evaluated in a blinded 
fashion by two examiners including one specialized uropathologist.  
Mast cells were counted at 100 x magnification. The mast cells were scored according to their 
location in the urothelium, lamina propria or detrusor musculature. Mast cells residing in the 
stroma were counted per square mm, using a grid. Three different areas in each resection were 
counted and a mean value was calculated. When possible, mast cells located in the detrusor were 
also counted by the same technique.  The urothelial mast cells were counted using a line width of 
1 mm (Paper III). 
α-SMA-positive and α-SMA-negative fibroblast-like cells were counted at 400 x magnification 
per 4x250 μm, using a grid. All round cells, mast cells, endothelial cells and smooth muscle 
cells were avoided in the counting process. The α-SMA-positive fibroblast-like cells were 
counted in the subepithelial compartment, in urothelial covered tissue, above the lamina 
muscularis mucosa, avoiding the most ulcerated areas (Paper IV). 
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RESULTS 
 
Paper I: 
The median side effect score after six instillations were 7 and 6, out of maximum 36, in patients 
with Type 3C BPS/IC and nonulcer BPS/IC, respectively. Side effects after instillations of 
DMSO were common, the most frequent being sensation of urethral irritation/pain in 48 % of 
the patients after the first instillation. For patients with Type 3C BPS/IC a significant difference 
could be seen when comparing experienced side effects during the first three instillations with the 
three following. When comparing patients, who responded well to treatment with those who did 
not, neither a difference in the character of side effects nor a relation of side effects to efficacy 
could be seen. With exception of one sepsis episode, no serious side effects or complications 
were noted. We were not able to demonstrate a difference in side effects between the two 
subtypes of BPS/IC. 
 
Patients 
0
2
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10
12
14
0–4 5–9 10–14 15–18 Total score 
Fig 4 Distribution of total side-effect scores for the six instillations. 
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Paper II: 
In 28 out of 34 patients with Type 3C BPS/IC did the initial surgical procedure result in 
complete symptom resolution. Of the remaining six patients, four could successfully be managed 
by a supplementary diversion procedure, cystectomy or transurethral resection of lesions in the 
trigonal remnant, respectively.  
Only three of the 13 patients with nonulcer BPS/IC experienced symptom resolution after 
reconstructive surgery and two out of these required a supravesical diversion procedure. 
Eight patients had a supplementary secondary simplex cystectomy in an attempt to treat 
persistent suprapubic pain, without improvement. Out of the 25 patients with initial ICP, 
continent orthotopic urinary diversion or caecocystoplasty, 13 required clean intermittent self-
catheterization at various stages during follow-up. 
Early intra- and postoperative complications were few. However, the need for reoperations in 
patients with nonulcer BPS/IC having undergone continent urinary diversion was high, mainly 
related to nipple valve problems. Widened ureteral orifices with vesicoureteral reflux seem very 
common following ICP, however not resulting in discernible clinical consequences. There was no 
finding of malignant change. 
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Paper III: 
The median time of improvement in months after each TURB was four, two and six and a half 
months, respectively. Although single patients responded well to treatment, in this limited series 
there was no homogeneous good responder group. Median mast cell density in the lamina 
propria was high.  
 
 
 
Fig 5  A and B: Adjacent sections of urinary bladder from patient with Type 3C BPS/IC. Intact urothelium 
(U) and inflammatory cells in lamina propria (LP) as demonstrated with staining by Hematoxylin and eosin (A). 
Occasional mast cells are seen within the urothelium (arrow) but more frequent in the lamina propria identified by 
tryptase immunehistochemical staining (B). Original magnification x 200. Bar is 100 μm. C and D: Detrusor 
muscle shows intrafascicular fibrosis, van Gieson (C). Frequent mast cells within the muscle fiber identified by 
tryptase immunehistochemical staining (D). Original magnification x100. Bar is 100 μm. 
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No statistically significant correlation between mast cell density in the lamina propria and the 
duration of symptom could be demonstrated. After the third TURB, five of the 12 patients were 
offered major reconstructive surgery due to end-stage disease with a small contracted bladder,  
since a response to TURB could no longer be expected. Bladder reconstruction was performed in 
one case. There was a positive correlation between a high mast cell numbers in the urothelium at 
the third TURB and the risk of developing end-stage disease. 
 
 
    TURB 1       TURB 2      TURB 3   
Gender MC dens Duration F/SR   MC dens Duration F/SR  MC dens Duration F/SR 
m 68 0,5 SR   64 0,5 SR  83 5 SR 
m 105 14 F   55 14 F  80 24 F 
f 78 2 SR   94 1 SR  56 2 SR 
f 77 4 F   88 1,5 SR  52 29 F 
m 69 5 F   104 2 F  62 4 SR 
m 80 12 F   68 3 F  55 2 SR 
f 68 8 F   83 0,5 SR  75 13 F 
f 48 1 SR   41 0 SR  47 12 F 
f 90 14 F   78 36 F  71 6 SR 
f 118 1 SR   134 2 F  79 3 SR 
f 128 1,5 SR   33 11 F  107 32 F 
f 161 4 F   96 6 F  51 7 F 
 
Table 4 Mast cell density and outcome after TURB. TURB 1,2 3= first, second and third TURB. MC 
dens=mast cell density, Duration=duration of symptom amelioration after TURB. F=fair responders. 
SR=short-term responders. m=male. f= female. 
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Paper IV 
Density of α-SMA+/ α-SMA- fibroblast-like cells seemed constant and no statistically 
significant change in density with increasing number of TURB`s could be seen, see Table 5.  
However, when comparing distribution of α-SMA+ fibroblast-like cells contra α-SMA- 
fibroblast-like cells at each TURB, an overweight of α-SMA + fibroblast-like cells compared to 
α-SMA - fibroblast-like cells was identified statistically significant only in patients with normal 
bladder capacity and not in patients with end-stage disease.  
 
  α-SMA+1 α-SMA-1 α-SMA+2 α-SMA-2 α-SMA+3 α-SMA-3 End-stage
M 18 18 5 12 3 6 X 
M 8 14 19 15 11 3   
F 8 11 23 10 22 21   
F 19 2 23 26 38 12   
M 28 7 14 6 21 14 X 
M 20 17 20 19 12 6 X 
F 26 25 44 32 14 8   
F 69 15 7 8 12 20   
F 24 9 6 8 34 6   
F 10 16 11 22 31 13 X 
F 36 4 33 16 19 6   
F 18 14 27 10 27 17   
 
Table 5  Density of α-SMA+ and α -SMA- fibroblast-like cells (per mm2) at first (α -SMA+1 and α -
SMA-1), second (α -SMA+2 and α -SMA-2) and third (α -SMA+3 and α -SMA-3) TURB.  
M= male, F= female. X= end-stage 
41 
DISCUSSION 
Several factors have limited progress in the understanding of BPS/IC, including lack of objective 
diagnostic criteria, unpredictable symptom fluctuation, and the variability of symptoms, objective 
findings and treatment outcomes. Furthermore, although a feline model has been used in some 
studies155-157 no ideal animal model mimics the evaluation of symptoms in humans, limiting our 
understanding of pathophysiology. In recent publications, the need for subdivision of BPS/IC 
has been increasingly recognized 81,86,158-161, since the two subtypes have shown to have different 
histopathological, immunological and neurobiological features55, 60, 75, 162-168.  
 
DMSO is a standard treatment of BPS/IC, one of few to stand the test of time. The issue of 
side-effects has only casually been addressed in previous reports on intravesical instillation 
therapy with DMSO. In Paper I we could report that side-effects after a single 6-week instillation 
series were common but fairly mild, except from one sepsis episode. It is usual for patients with 
Type 3C and nonulcer BPS/IC to diverge in response to different therapies141, 145, 153, 169, 170. 
Interestingly, a significant difference in side-effects during the first three installations compared 
to the following three instillations could be seen in patients with Type 3C BPS/IC but not in 
nonulcer BPS patients. An explanation could be that since patients with Type 3C BPS/IC often 
have severely damaged urothelium the solution reaches underlying nerves in very high 
concentrations. The mechanisms by which DMSO exerts a favourable effect in BPS/IC patients 
remain unclear but some of the beneficial effects of DMSO might be through modulation of 
sensory nerves with stimulation of bladder afferent pathways and nitric oxide (NO) release from 
afferent neurons171. In favour of this hypothesis is the finding that treatment with DMSO does 
not result in any histological improvement172. Somewhat in conflict with this hypothesis, though, 
is the fact that among the seven patients reporting symptom amelioration, either after a single 6-
week instillation or during maintenance treatment at follow-up, no overrepresentation of patients 
with Type 3C BPS/IC could be seen. However, the number of patients included in the study was 
too small to draw conclusions about subtypes with a reasonably degree of certainty. When 
studying the functional capacity, frequency and visual analogue scale (VAS) at baseline and 
follow-up in the patients who had only received DMSO instillations or were on maintenance 
treatment, no convincing pattern concerning the objective data could be seen to support the 
subjective report by the patient on improvement. Speculatively, some of these patients represent 
examples of development of successful coping mechanisms. In other studies, overall relapse rate 
ranges from 35 to 40 per cent, with an average follow-up period of 1-2 years105, 173-176. 
42 
Intravesical application of medications establishes high concentrations at the target site with few 
systemic side effects. However, the need for intermittent catheterization, which is often painful in 
BPS patients, the cost and the potential risk of infection are drawbacks. There are reports of 
successful treatment with intravesical lidocaine177, 178, but an obvious disadvantage with this 
method is that very frequent instillations are needed. Frequent self-catheterization usually is so 
painful in this category of patients that this mode of treatment would be too difficult to accept. 
Like DMSO instillations, treatment with intravesical PPS seem to be possible with maintenance 
treatment as well. In one study including 10 patients receiving PPS and placebo respectively, at 
three months, four and two patients gained symptomatic relief. However, at 18 months, 
symptoms were relieved in eight patients while still receiving PPS instillations and in four without 
treatment114. However, since the initial effect is quite modest some problems with compliance 
might be expected. Instillations with BCG has been reported to be tolerated, just like DMSO, but 
unfortunately found to be inefficient as well as potentially harmful 110,113.  DMSO is considered a 
standard treatment, possibly also first-line treatment, for patients with nonulcer BPS/IC and 
bearing that in mind, it is reassuring to find good safety and tolerability for this kind of treatment. 
Admittedly, a limitation of the study is that the adopted scoring system, used to evaluate side-
effects, is not a validated one, but the strength is the originality, since side effects have not 
specifically been studied before.  
 
In BPS/IC, a group of patients always remain in whom all forms of therapy fail and where the 
disease is severe enough to warrant a major operation. Oravisto4 estimated that 1 of every 10 
patients with interstitial cystitis has a severe form of the disease, an estimation later suggested by 
others179. Paper II is one of the hitherto largest studies, with longest follow-up, for patients with 
BPS/IC subjected to reconstructive surgery for refractory symptoms. The conclusions drawn 
from the study is that reconstructive surgery in patients with BPS/IC renders an eminent chance 
of symptom improvement in patients with end-stage Type 3C BPS/IC. To take into 
consideration, though, is the fact that, although BPS/IC is severely detrimental to quality of life, 
it has no direct mortality while major surgery includes a risk that is not negligible of morbidity 
and mortality. A decision on surgical reconstruction should therefore not be embarked upon 
without due consideration. Early intra- and postoperative complications were few. However, the 
complication rate in the group of nonulcer patients in our study was high, mainly due to nipple 
valve related problems. Several previous studies have shown that patients with BPS/IC or other 
benign functional or inflammatory disease have significantly worse outcomes after reconstructive 
surgery than patients with malignant disease, spinal cord injury or malformation180, 181.  
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 Concerning the surgical approach to the bladder, there is nearly general agreement that at least 
the supratrigonal part of the bladder should be resected to avoid unfavourable outcomes. 
Additionally, some perform a subtrigonal resection as well182, 183. The advantage of a trigone-
preserving procedure is that the ureteral orifices are left in situ, avoiding complications associated 
with ureteral reimplantation. Surgical failure to improve the symptoms of a patient with BPS/IC 
is thought to be due to inflammation in the trigone remnant184-186. Although this may be true, we 
do not routinely perform concomitant cystectomy. We believe this is an unusual complication in 
patients with Type 3C BPS/IC, affecting only two patients in the study, both with excellent 
outcome after TURB of the lesion and cystectomy, respectively. In contrast, eight patients with 
nonulcer BPS unsuccessfully underwent supplementary secondary simplex cystectomy in an 
attempt to overcome persistent suprapubic pain.  
There are far more extensive approaches to deal with postoperative persisting pain, maybe most 
radically shown by Baskin et al187, performing hysterectomy, bilateral ooforectomy, presacral 
neurectomy and total cystectomy with ileal loop urinary diversion in a 19-year-old woman, with 
resistant pain. Other results can be more difficult to understand in terms of complications, with 
reports on 40 per cent experiencing mild degree of dyspareunia after cystectomy including 
resection of the urethra proximal to the pubourethral ligaments, but surprisingly without 
disturbance of sexual life188. 
 
It is often stated, and quite universally accepted, that surgical therapy of BPS/IC never should be 
considered as first-line therapy and the importance of excluding possible mimicking conditions is 
emphasised. However, the importance of undertaking subtyping of the patients has not been 
equally accepted and not performed as consistently. Therefore, some of the previous results 
reported from reconstructive surgery on BPS/IC patients may be misguidedly discouraging.  
In the present series 82 per cent of the patients with Type 3C BPS/IC reported complete 
symptom resolution after the initial surgery and 94 per cent after supplementary surgery. The 
remaining 6 per cent were represented by late failures due to comorbidity such as cerebrovascular 
disease. These results are in accordance with earlier studies on caecocystoplasty for patients with 
Type 3C BPS/IC179, 189-191.  
Unfortunately, only 8 per cent of the patients with nonulcer BPS experienced symptom 
resolution after major reconstructive surgery, increasing to 23% if a supplementary supravesical 
diversion procedure was performed. This is at variance with a report on 100 per cent successful 
outcome, after bladder substitution by ileal neobladder, in 35 patients diagnosed with intractable 
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BPS/IC but with no Hunner`s lesion on cystoscopy188. Whitmore et al192 reported 80 per cent 
(12/15) success rate, with success defined as subjective improvement with intact reconstruction, 
but not mentioning subclassification. As a step in patient evaluation before cystoplasty, 
cystoscopy is often advocated, but primarily to exclude carcinoma in situ in patients with irritative 
bladder symptoms believed to be caused by interstitial cystitis193. Some argue that patients with 
improvement after surgery are more likely to have had a small bladder capacity under anaesthesia 
and a bloody effluent after hydrodistension preoperatively, and that the presence of 
glomerulations or ulcers is less predictive194. However, if only patients with Type 3C BPS/IC had 
been considered for reconstructive surgery, most likely the possibility for a good outcome had 
been optimized. Inadequate diagnostics accounts for the great part of conflicting results reported 
in the literature.   
Our study compared results of different types of surgical procedures, performed for two different 
groups of patients, and attributing the different surgical outcome solely to the two groups of 
patients differing in their BPS/IC subtypes. Presentation of consistent pre/postoperative data, 
including pain scores, would of course have given the study a more robust design instead of just 
stating ‘Residual pain’, ‘Residual frequency’ or ‘Good’, but unfortunately this information quite 
often was missing in this study covering a quarter of a century. My opinion, though, is that due to 
the fact that BPS/IC is a benign disorder and reconstructive surgery is a major operation, a 
statistically significant decrease in VAS from e.g. VAS 10 to VAS 6 might still be of questionable 
relevance to the patient. Thus, the somewhat simplistic grading of improvement used may 
capture the entire outcome as good as, or maybe even better, than such a scale.  
 
No finding of malignant transformation was noted in the patients subjected to ileocystoplasty. As 
for diversionary procedures, the potential risk of developing carcinoma in the defunctionalized 
bladder is frequently discussed, but only five cases were found after a comprehensive review of 
the literature by Garvin et al195. Quite in accordance with previous reports152, 153, 196, a significant 
number of patients (13/25) required clean intermittent self-catheterization at various stages 
during follow-up. 
 
 
Today the urothelium is no longer looked upon as just an inert barrier but rather as a very active 
component of the bladder wall, that exhibits specialized sensory and signalling properties. Some 
of the symptoms experienced by patients with BPS/IC may be caused by vasoactive and 
inflammatory mediators secreted by mast cells. Tryptase, which is increased in the urine of 
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BPS/IC, causes microvascular leakage and stimulation of protease-activated receptors (PARs), 
resulting in inflammation and submucosal neuronal hyperexcitability197, 198. Another mast cell 
mediator with vasodilatatory properties is vascular endothelial growth factor (VEGF), which is 
overexpressed in bladders, and may add to the hypervascularity and glomerulations characteristic 
of BPS/IC199. In paper III mast cell density in the lamina propria was assessed for possible 
correlation with duration of symptom amelioration after TURB. Our hypothesis was that, since 
mast cells by tradition have been thought to reflect intensity and grade of disease in patients with 
Type 3C BPS/IC, patients with a high mast cell density would respond more favourably to 
TURB.  
 
Simmons200 was the first to report that the number of mast cells in bladder tissue was increased in 
BPS/IC patients. Subsequently, it was reported that the increase in the number of mast cells in 
the bladder muscularis had diagnostic significance68, 71, 201, 202. However, it became clear that the 
number of mast cells varied depending on differences in staining methods. Some reports69, 203 
indicate that prolonged toluidine blue staining tends to cause an increase in the number of 
detected mast cells in lamina propria and detrusor muscle and this tendency is particularly 
apparent in Type 3C BPS/IC. Other reports indicate that the number of mast cells is increased in 
the lamina propria and detrusor in both Type 3C BPS/IC and nonulcer BPS/IC71. Meanwhile, 
some report that no significant difference is observed in the number of mast cells between 
nonulcer BPS/IC and control tissue164. Tryptase immunocytochemistry is the most accurate 
technique for histological examination of human mast cells, identifying a unique protease present 
in both types of human mast cells. When this technique was used a 6- to 10-fold increase in mast 
cells in classic IC and a 2-fold increase in patients with nonulcer IC, compared with controls, 
were seen75.  
 
In the literature, the significance of the association between the clinical presentation of BPS/IC 
and increased numbers of mast cells is conflicting. In a previous study by Holm-Bentzen et al83 
no variation in severity of symptoms ( pain, dysuria, frequency and nocturia) could be seen in 
patients with or without detrusor mastocytosis, defined as 28 mast cells per mm2. However, 
patients with mastocytosis had hematuria more often and had a significantly reduced bladder 
capacity, indicating that it concerned patients with Type 3C BPS/IC.  Lynes et al reported on lack 
of correlation between mast cell density and severity of clinical symptoms, but symptoms may be 
as severe in the two main types of BPS/IC. However, mast cell density did correlate with degree 
of submucosal inflammation70. Furthermore, neither mast cell density, nor the histological state 
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of the trigone have been found to be reliable predictors of outcome after supratrigonal 
cystectomy152. The only significant correlation between the clinical symptoms and pathological 
findings reported to date has been that of nocturia and an increased number of tryptase-positive 
urothelial mast cells73. Rudick et al76 induced a neurogenic cystitis associated with lamina propria 
mast cell accumulation by infecting mice with pseudorabies virus (PRV). They reported that mast 
cells promote cystitis pain and bladder pathophysiology through the separable actions of 
histamine and tumor necrosis factor,TNF, respectively. Pelvic pain developed normally in TNF- 
and TNF receptor-deficient mice, while bladder pathophysiology was abrogated. Conversely, 
genetic or pharmacologic disruption of histamine receptor, H1R or H2R, attenuated pelvic pain 
without altering pathophysiology. Their results suggest that mast cells contribute to both pain and 
bladder inflammation and pathophysiology through the divergent actions of histamine and TNF, 
respectively. 
 
Outcomes after TURB in Paper III, with median durations of symptom remission of 4, 2 and 6.5 
months, were far less convincing than in previously reported series18, 145, 146. This may be due to a 
sample size bias. However, in the hitherto largest series on patients with Hunner’s lesions treated 
with TURB18 four groups emerged: long-term good responders, short-term good responders, 
patients with slow (>2 years) progression to end stage disease with contracted bladder and 
patients with rapid (<2 years) progression to end-stage disease. In the present series 42 per cent 
of the patients would be allocated to the latter two groups, compared with 21 per cent of the 
patients in the study by Peeker et al18 and, speculatively, this may explain the difference in 
outcome. 
 
It has been suggested that mast cells counts >20 cells/mm2  should be defined as mastocytosis88 
and that this definition in bladder muscle have an 88 per cent diagnostic specificity and a 95 per 
cent diagnostic sensitivity for IC202.  We reported on a median mast cell density in the lamina 
propria at the first, second and third TURB of 90, 78 and 68/mm2, respectively. No statistically 
significant correlation between mast cell density in the lamina propria and duration of symptom 
amelioration could be seen after the first, second or third TURB, and this was also true when 
correlating duration of symptom remission with mast cell density in other tissue compartments.  
The positive correlation between a high mast cell number in the urothelium at the third TURB 
and the risk of developing end-stage disease was surprising, since it has previously been suggested 
that patients with end stage disease display very few inflammatory signs on histopathological 
examination153. In summary, our hypothesis that mast cell density could be a predictor of clinical 
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outcome of TURB, was discarded. Our results suggest that inflammation caused by mast cells 
may not be directly associated with the grade of symptoms, as has earlier been thought, but mast 
cells are still an important diagnostic parameter. 
 
 
In patients diagnosed with BPS/IC, presenting with incapacitating urinary frequency and 
nocturia, detrusor fibrosis can be seen in bladder biopsy specimens. This is a finding 
significantly associated with failure of standard urological therapy, resulting in a more intense 
treatment204. As mentioned before, patients with Type 3C BPS/IC seem to develop fibrosis in 
different extent and with varying time18. To date, not much research about bladder detrusor 
fibrosis has been undertaken and the cellular mechanisms of inflammation in BPS/IC and the 
processes leading to detrusor fibrosis are not yet understood. Speculatively, myofibroblasts 
might have a role in the evolution towards bladder contracture. The development of bladder 
contracture is no doubt an intrinsic event as a result of chronic inflammation. Whether 
repeated TURB may enhance the process leading to bladder contracture is an open question. 
In the short term, increase of bladder capacity has been registered123 , paralleled by successful 
outcome after TURB, possibly due to the removal of intramural nerve endings engaged by the 
inflammatory process18. Since patients treated with TURB often need repeated resections, the 
possibility that treatment might enhance the process towards end-stage disease can not be 
excluded. In Paper IV an attempt to explore these hypotheses was made. The density of α-
SMA positive and α-SMA negative fibroblast-like cells in patients recently diagnosed with Type 
3C BPS/IC and the changes of density of these cells with repeated TURB were examined. No 
statistically significant increase or decrease in α-SMA positive and α-SMA negative fibroblast-
like cells could be seen when comparing density of both types of cells with increased number 
of TURB, suggesting that myofibroblast activation might be one factor of importance in the 
development towards bladder contracture, independent of external influence like TURB.  
 
Chronic inflammation has been related to end-organ failure due to fibrosis in a variety of 
organs205-208. In some inflammatory diseases, fibrosis is related to YKL-40. YKL-40 is a 40kDa 
heparin-, chitin- and collagen-binding, phylogenetically highly conserved glycoprotein209, 
promoting growth of fibroblast cell lines through activation of MAP kinase and PI3K signalling 
pathways propagating mitogenic signals210. Excessive production of YKL-40, through binding to 
and modulating collagen formation, may cause extracellular matrix accumulation with tissue 
fibrosis211. Recent studies have shown a correlation between the mammalian glycoprotein YKL-
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40 and fibrosis in diseases such as liver fibrosis212-214, rheumatoid arthritis215-217, atherosclerosis218, 
219, asthma220, and chronic obstructive lung disease221. In a study by Richter et al222 detrusor 
fibrosis was significantly associated with numbers of YKL-40-positive cells and mast cells. A 
significant inverse correlation was seen between bladder capacity and number of YKL-40-
positive cells and mast cells. However, no significant correlation between clinico-pathological 
parameters (nocturia, mucosal bleeding and treatment intensity) and detected cell numbers or 
concentrations of YKL-40 in serum and urine were seen. 
 
A previous study has reported mast cell involvement, showing that mast cell chymase seems to 
stimulate collagen synthesis by fibroblasts in neurogenic bladder fibrosis223. Also, a tryptase 
present in large amounts in MCTC is fibroblast growth factor, promoting proliferation of 
fibroblasts and fibrosis. The involvement of tryptase in progression to atrophic bladder is also 
proposed in view of the inverse relationship between the number of MCTC in the muscularis and 
the bladder capacity as an indication of the degree of IC progress. Furthermore, it has been 
claimed that the chymase present in MCTC produces stem cell proliferation factors in the soluble 
form from the mucosa of stroma cells adjacent to mast cells and accumulates in mast cells in 
certain regions, promoting production, proliferation and differentiation of mast cells224, 225. 
However, as mentioned before, contradictory results have been reported in the numerous studies 
on the value of mast cell counts in biopsies of patients with BPS/IC. For example, some studies 
have reported a significant increase in detrusor mast cell counts compared to controls68,71, 202, 204, 
226, while another has not164.  
 
The α-SMA positive fibroblast-like cells were counted in tissue covered by urothelium in the 
subepithelial compartment, above the lamina muscularis mucosa, avoiding the most ulcerated 
areas. The reason for this was to avoid any activated myofibroblast in ulcers, most probably 
being present as a normal component during the healing process. In that way cells generally 
related to the disease process should be more reliably identified. Still, since there is currently no 
specific cellular marker and considerable variation in reported findings, confirmation of the 
presence of this cell type requires a detailed survey of multiple features, particularly 
morphology, phenotype and ultrastructure227. Examination in this series was done only with 
light microscopic techniques; we have therefore chosen to call the cells α-SMA positive and α-
SMA negative fibroblast-like cells. Combination of light and electron microscopic techniques 
to ascertain the cellular phenotype would more likely have ascertained the results of this study, 
but is arduous and should be a step in future research on the subject.  
49 
 The upper limit for anaesthetic bladder capacity in Paper IV of 250 ml is arbitrary and it has to 
be noted that there is no generally accepted definition of end-stage Type 3C BPS/IC. At this 
stage the patients often primarily complain of intolerable urinary frequency while there is little 
pain. Using the suggested dividing line there was an interesting finding.  In the group of eight 
patients, apparently at an earlier stage of the disease, a statistically significant overweight of α-
SMA positive fibroblast-like cells at the third TURB was found. This may lead to the 
assumption that patients with a substantial time of illness are the only ones to present 
significant myofibroblast overweight while no such findings seemed to be associated with 
earlier TURB episodes or established bladder contracture.  
The present pilot study thus suggests that myofibroblast activation might be one factor of 
importance in the development towards bladder contracture, independent of external influence 
like TURB. This is a first attempt to take the role of myofibroblastic activity in BPS/IC, 
complicated by bladder contracture, into consideration. Despite the limited size of the material, 
the lack of controls and the need for more sophisticated histological techniques, like electron 
microscopy, we think that the results of this pilot study are of sufficient interest to warrant 
more extensive studies. 
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CONCLUSIONS 
Intravesical instillation with DMSO appears to be associated with a reasonably degree of 
discomfort, especially considering the potential benefit of the treatment in both subtypes of 
BPS/IC (Paper I). For patients with Type 3C BPS/IC, TURB seems to be a more efficacious 
treatment option. However, mast cell density does not appear to correlate with duration of 
symptom amelioration after complete transurethral resection of Hunner`s lesions, neither in the 
lamina propria nor in the urothelium or the detrusor (Paper III).  
TURB does not seem to result in enhanced progress towards end-stage disease. The findings of 
an overweight of α-SMA positive fibroblast-like cells in patients with signs of active disease, 
expressed by repeated TURB`s, might represent a time dependent factor of myofibroblast 
activation eventually resulting in a contracted bladder (Paper IV).  
When conventional therapies no longer offer any symptom amelioration, but the patient present 
with bladder contracture and/or intolerable symptoms, reconstructive surgery can be an 
appropriate last resort, but only in patients with Type 3C BPS/IC. The most important 
determinant in the decision to embark upon major reconstructive surgery is the assessment of 
subtype and stage of the disease (Paper II). 
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